Cullinan Therapeutics (CGEM) grants director 25,319 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cullinan Therapeutics director Anthony Rosenberg received a grant of stock options covering 25,319 shares of Common Stock. The options have an exercise price of $13.55 per share and will vest in full on the earlier of June 16, 2027 or the company’s next annual meeting, contingent on his continued board service. Following this compensation grant, he holds options for 25,319 underlying shares directly, with no open-market buying or selling reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rosenberg Anthony

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,319	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,319 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 25,319 shares Exercise price: $13.55 per share Underlying shares: 25,319 shares +3 more

6 metrics

Option grant size 25,319 shares Stock Option (Right to Buy) granted to director Anthony Rosenberg

Exercise price $13.55 per share Exercise price of newly granted stock options

Underlying shares 25,319 shares Common Stock underlying the option award

Post-grant derivative holdings 25,319 options Total derivative securities held following the transaction

Vesting date trigger June 16, 2027 Full vesting or earlier at next annual meeting, if sooner

Expiration date June 16, 2026 Option expiration date reported for the award

Key Terms

Stock Option (Right to Buy), Common Stock, Grant, award, or other acquisition, derivative, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

vest in full financial

"which shall vest in full on the earlier of (i) June 16, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosenberg Anthony

(Last)

(First)

(Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.55	06/16/2026		A		25,319		⁽¹⁾	06/16/2026	Common Stock	25,319	$0	25,319	D

Explanation of Responses:

1. The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) report for Anthony Rosenberg?

Cullinan Therapeutics reported a compensation-related grant to director Anthony Rosenberg of stock options for 25,319 shares of Common Stock at a $13.55 exercise price. This Form 4 does not show any open-market purchases or sales, only the new option award.

How many Cullinan Therapeutics (CGEM) shares are covered by the new option grant?

The new option granted to Anthony Rosenberg covers 25,319 shares of Cullinan Therapeutics Common Stock. This represents the full amount of underlying shares associated with this award and matches his total derivative holdings reported following the transaction in the Form 4.

What is the exercise price of Anthony Rosenberg’s Cullinan Therapeutics (CGEM) stock options?

The granted stock options have an exercise price of $13.55 per share. This means Rosenberg can buy Cullinan Therapeutics Common Stock at $13.55 once the options vest, subject to the terms and timing described in the award footnote.

When do Anthony Rosenberg’s Cullinan Therapeutics (CGEM) options vest?

The option award vests in full on the earlier of June 16, 2027 or the date of Cullinan Therapeutics’ next annual meeting. Vesting is conditioned on Rosenberg’s continued service as a director through the applicable vesting date as stated in the footnote.

Did Anthony Rosenberg buy or sell Cullinan Therapeutics (CGEM) shares in the market?

The Form 4 shows no open-market buying or selling by Anthony Rosenberg. It reports only a grant of stock options as a compensation award, coded as an acquisition (Code A), with 25,319 underlying shares and no sale transactions disclosed.

What type of security was granted to Anthony Rosenberg by Cullinan Therapeutics (CGEM)?

Anthony Rosenberg received a Stock Option (Right to Buy) linked to Cullinan Therapeutics Common Stock. The option covers 25,319 underlying shares, features a $13.55 exercise price, and is reported as a derivative security on the Form 4 insider trading report.